LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Alcon Inc

Open

SectorGezondheidszorg

79.64 0.04

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

79.24

Max

80.04

Belangrijke statistieken

By Trading Economics

Inkomsten

-167M

183M

Verkoop

123M

2.6B

K/W

Sectorgemiddelde

36.949

35.733

Dividendrendement

0.42

Winstmarge

7.058

Werknemers

25,000

EBITDA

-213M

250M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+23.1% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.42%

3.13%

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4.3B

40B

Vorige openingsprijs

79.6

Vorige sluitingsprijs

79.64

Nieuwssentiment

By Acuity

10%

90%

13 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Alcon Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 sep 2025, 23:07 UTC

Acquisities, Fusies, Overnames

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

20 aug 2025, 17:21 UTC

Winsten
Belangrijke Marktbewegers

Alcon Shares Sink After Cut to Fiscal Year Sales Guidance

20 aug 2025, 08:46 UTC

Winsten
Belangrijke Marktbewegers

Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit

5 aug 2025, 10:10 UTC

Acquisities, Fusies, Overnames

Alcon to Buy Staar Surgical for $1.5 Billion

14 mei 2025, 15:56 UTC

Winsten
Belangrijke Marktbewegers

Alcon Shares Fall After Lowering 2025 Outlook

26 mrt 2025, 21:22 UTC

Acquisities, Fusies, Overnames

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

20 aug 2025, 17:06 UTC

Winsten
Belangrijke Marktbewegers

Alcon Shares Sink After Cut to FY Sales Guidance

19 aug 2025, 20:32 UTC

Winsten
Acquisities, Fusies, Overnames

Alcon Cuts 2025 View To Sales $10.3B-$10.4B >ALC.EB

19 aug 2025, 20:31 UTC

Winsten
Acquisities, Fusies, Overnames

Alcon 2Q EPS 35c >ALC.EB

19 aug 2025, 20:30 UTC

Winsten
Acquisities, Fusies, Overnames

Alcon 2Q Sales $2.58B >ALC.EB

19 aug 2025, 20:30 UTC

Winsten
Acquisities, Fusies, Overnames

Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr And Announced Acquisition Of STAAR Surgical >ALC

8 aug 2025, 13:40 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Staar Surgical's Top Holder Questions Deal -- Market Talk

5 aug 2025, 05:07 UTC

Acquisities, Fusies, Overnames

Alcon Deal Puts STARR Equity Value at Approximately $1.5 Billion. >ALC.EB

5 aug 2025, 05:07 UTC

Acquisities, Fusies, Overnames

Alcon Will Purchase All Outstanding Shares of STAAR Common Stock for $28 Per Share in Cash >ALC.EB

5 aug 2025, 05:07 UTC

Acquisities, Fusies, Overnames

Alcon Deal Represents 51% Premium to Closing Price of STAAR Common Stock on Aug. 4 >ALC.EB

5 aug 2025, 05:07 UTC

Acquisities, Fusies, Overnames

Alcon Agrees to Acquire STAAR Surgical >ALC STAA

5 aug 2025, 05:01 UTC

Acquisities, Fusies, Overnames

Alcon Agrees To Acquire STAAR Surgical >ALC STAA

7 jul 2025, 12:00 UTC

Acquisities, Fusies, Overnames

Alcon To Acquire LumiThera And Its Photobiomodulation Device For The Treatment Of Early And Intermediate Dry Age-Related Macular Degeneration (AMD) >ALC

30 mei 2025, 06:32 UTC

Marktinformatie
Winsten

Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk

22 mei 2025, 20:46 UTC

Acquisities, Fusies, Overnames

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

13 mei 2025, 20:32 UTC

Winsten

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 mei 2025, 20:31 UTC

Winsten

Alcon 1Q Sales $2.45B >ALC.EB

13 mei 2025, 20:30 UTC

Winsten

Alcon 1Q Rev $2.47B >ALC.EB

13 mei 2025, 20:30 UTC

Winsten

Alcon 1Q EPS 70c >ALC.EB

8 apr 2025, 08:20 UTC

Marktinformatie

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

26 mrt 2025, 21:55 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26 mrt 2025, 20:33 UTC

Acquisities, Fusies, Overnames

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26 mrt 2025, 20:32 UTC

Acquisities, Fusies, Overnames

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26 mrt 2025, 20:32 UTC

Acquisities, Fusies, Overnames

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26 mrt 2025, 20:31 UTC

Acquisities, Fusies, Overnames

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

Peer Vergelijking

Prijswijziging

Alcon Inc Prognose

Koersdoel

By TipRanks

23.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 98.69 USD  23.1%

Hoogste 119.067 USD

Laagste 77.53 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Alcon Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

13

Buy

5

Hold

0

Sell

Technische score

By Trading Central

95.77 / 97.61Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

13 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
help-icon Live chat